Renal fibrosis is a common endpoint for many chronic kidney diseases. Extracellular matrix (ECM) from myofibroblasts causes progressive scarring and organ failure. The mechanisms underlying fibrogenesis and how it is sustained are incompletely understood. Here, we show that the transcription factor, Sex determining region Y-box 9 (SOX9), is required for kidney fibrosis. From genome-wide analysis we identify Neuron navigator 3 (NAV3) downstream of SOX9. NAV3 was upregulated in kidney disease in patients and following renal injury in mice colocalised with SOX9. By establishing an in vitro model of renal pericyte transition to myofibroblast we demonstrated that NAV3 is required for multiple aspects of fibrogenesis including actin polymerization linked to cell migration and sustaining SOX9 and active YAP1 levels. In summary, our work discovers novel SOX9-NAV3-YAP1/SOX9 circuitry as a new mechanism to explain the progression of kidney fibrosis and points to NAV3 as a novel target for pharmacological intervention.
Introduction
Fibrotic scarring is common to many chronic kidney diseases (CKD). It is characterized by the pathological deposition of collagen-rich extracellular matrix (ECM) proteins from profibrotic ('activated') myofibroblasts in response to kidney injury and leads to loss of renal function [1] [2] [3] . The fibrotic ECM increases organ stiffness. This rigidity perpetuates disease progression 4, 5 . Despite renal fibrosis being a significant contributor to patient morbidity and mortality there are no anti-fibrotic drugs currently approved. In large part this reflects limited understanding of the underlying mechanisms, against which new therapies might be targeted, including how renal myofibroblasts arise.
Fibrotic ECM signals via cell-surface integrins to control the cytoskeletal and mechanical properties of myofibroblasts 4, 6 . Previously, we identified cytoskeletal alterations in liver myofibroblasts, downstream of integrin β1, mediated through actomyosin signaling via P21-activated kinase (PAK1) and the mechanical transcriptional effector, Yes-associated protein 1 (YAP1) 7, 8 . In kidney, similar mechanisms have been invoked where YAP1 upregulates TGFβ, a potent profibrotic cytokine, to further activate myofibroblasts 9, 10 . Pharmacological inhibition of YAP1 has partly ameliorated fibrosis in both kidney 10, 11 and liver 7, 8 . These findings suggest value from considering mechanisms that might be shared across organs.
In liver, the transcription factor Sex determining region Y-box 9 (SOX9), downstream of TGFβ and YAP1, promotes fibrosis in vivo and in vitro by upregulating a wide array of genes encoding pathological ECM components 8, [12] [13] [14] [15] . SOX9 levels predict fibrosis disease progression within four years 8 . The concentration of circulating proteins encoded by SOX9-target genes, such as osteopontin and vimentin, also correlates with the severity of liver fibrosis 12 . SOX9 is known to be important in kidney development in mouse 16, 17 and human 18 . While it has been detected in renal fibrosis 19 , SOX9's role in vivo in renal fibrosis has been unaddressed and any putative mechanism of action unidentified.
How myofibroblast activation is perpetuated in progressive renal fibrosis is unknown.
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In this study, we hypothesized that if SOX9 was required for renal fibrosis in vivo, this would unlock an opportunity to discovery critical downstream target genes responsible for the profibrotic phenotype of renal myofibroblasts. We studied chronic kidney disease in patients and undertook SOX9 inactivation in the context of unilateral ureteric obstruction (UUO) in mouse to induce renal injury and fibrosis. We used transcriptomic deep sequencing (RNAseq) to pinpoint clusters of SOX9 target genes in vivo. We discovered and investigated Neuron navigator 3 (NAV3) as a target of SOX9 and novel mediator of myofibroblast function in kidney fibrosis. This included establishing a new model of pericyte activation into myofibroblasts. Together, the data prove the requirement for a critical transcription factor in promoting renal fibrosis, describe a new mechanism of action, and discover a novel target, NAV3, for therapeutic consideration.
Results

SOX9 is expressed in myofibroblasts in chronic kidney disease in human and mouse. By
immunohistochemistry nuclear SOX9 was detected in chronic interstitial nephritis consistent with previous reports of the transcription factor in regenerative tubular cells 20, 21 (Figure 1 ). In diabetic and membranous nephropathies, SOX9 could also be observed in some nuclei within the glomerulus (Figure 1 and Supplementary Figure 1 ). In addition, the transcription factor was apparent in the nuclei was observed in the brush border in the unaffected contralateral kidney, we corroborated our findings with in situ hybridization (ISH) for Sox9 ( Figure 2d ). Collectively, these data confirm that the distribution of SOX9 in myofibroblasts during renal fibrosis is the same in human and mouse, validating inactivation studies in mouse to discover SOX9 function in vivo. Delineating genome-wide pathways downstream of SOX9 in kidney fibrosis identifies Nav3. We wanted to discover what profibrotic genes were regulated by SOX9. Reassured that whole kidney analysis had detected clear differences for our user-defined genes, we undertook RNAseq in biological replicate following UUO on ipsilateral versus contralateral kidneys in Sox9 control and Sox9 null mice.
Following hierarchical analysis, differentially expressed genes clustered into four categories on heatmap (Figure 4a , Supplementary Figure 3 and RNAseq dataset E-MTAB-8429). In the second largest category, Cluster 3, loss of SOX9 returned gene expression that had been upregulated by fibrosis back to control levels. Cluster 3 from Figure 4a is expanded in Supplementary Figure 4 . By gene ontology, these 168 genes were heavily linked to fibrosis and ECM (Supplementary Figure 5 ).
Within the most highly ranked disease and functional category ('Cancer, connective tissue disorders, organismal injury and abnormalities') we identified Nav3, which was one of the fifteen most differentially expressed genes in the entire dataset (log2 fold change, -2.98 in response to SOX9 inactivation) ( Figure 4b and Supplementary Table 1 ). We verified the RNAseq findings by direct RT-qPCR. Nav3 transcription was increased in the fibrotic kidney post-UUO but returned to baseline levels when Sox9 was absent ( Figure 4c ). NAV3 is upregulated in kidney fibrosis. NAV3 has not been connected previously to any form of organ fibrosis or myofibroblast function. In normal mouse kidney, minimal NAV3 expression could be detected in and around vasculature adjacent to glomeruli (Figure 5a Taken together, these data indicate that NAV3 is dependent on and colocalizes with SOX9 in mouse and human renal fibrosis.
NAV3 is required by activated renal pericytes for cell migration and myofibroblast function.
Myofibroblasts and the mechanosensitive transcription factor, YAP1, downstream of profibrotic TGFβ, are central to interstitial renal fibrosis 10, 11, 22 . This is directly analogous to liver fibrosis, which in turn is dependent on the hepatic stellate cell (HSC). The HSC is a pericyte that when quiescent surrounds endothelial cells and upon activation migrates into areas of damage to lay down fibrotic ECM. HSC activation has been extensively studied in vitro by isolating quiescent cells by density gradient and culturing them on tissue culture plastic. We adapted this model to extract primary pericytes from normal mouse kidney. Directly comparable to their hepatic counterparts, on day 1 cells were rounded and lacked organized cytoplasmic α-SMA or nuclear SOX9 ( Figure 6a ). However, after culture for 14 days, again identical to activated HSCs, the pericytes had transitioned into a myofibroblast phenotype with filamentous α-SMA and robust nuclear detection of SOX9 ( Figure 6a ). We adopted the terms quiescent renal pericytes (QuiRPs) and activated renal pericytes (ARPs) for these two states. ARPs responded to TGFβ by increasing levels of SOX9, α-SMA and COL1 protein ( Figure 6b ). This new model allowed us to model renal fibrogenesis in vitro and study intracellular NAV3 function. NAV3 protein was barely detected in QuiRPs but strongly detected in ARPs when it organized linearly at the tips of actin filaments in the cell periphery, consistent with a role stabilizing microtubules in breast cancer cells ( Figure 6c ) 23 . Abrogating SOX9 in ARPs by siRNA reduced levels of α-Sma and Nav3, further demonstrating the dependence of Nav3 transcription on SOX9 (Figure 6d ). We inactivated NAV3 in ARPs by CRISPR/Cas9-mediated gene editing in three independent experiments (Supplementary Figure 7) . After 24h NAV3-inactivated ARPs had lost α-SMA and tubulin organization and reverted to being morphologically more similar to QuiRPs (Figure 7a ). Cells were less extended and linear organization of NAV3 was no longer apparent. In liver, activated HSCs are notable for their migration to areas of tissue injury. We used live cell tracking to follow 45 ARPs over 24h.
NAV3 inactivation reduced ARP migration compared to wildtype cells (Figure 7b-d ). Live cell imaging over 16h showed the fluorescence intensity by reporter labelling of endogenous F-actin was also significantly reduced in NAV3-deficient ARPs (Figure 7e -f). To extend these data to human, we isolated, cultured and then abrogated NAV3 levels in human renal fibroblasts. Consistent with the requirement for active YAP1 signaling in kidney fibrosis, diminution in NAV3 increased the ratio of inactive phosphoYAP to total YAP (Figure 7g ). We predicted this altered mechanosensing would alter nuclear membrane factors known to transduce alterations in cell tension and, indeed LAMIN A/C was also at least partially reduced following abrogation of NAV3. In combination, these data demonstrate NAV3 upregulation as renal pericytes transition into myofibroblasts and that NAV3 is required for the profibrotic phenotype including cytoskeletal organization and cell migration linked to the functional status of YAP1.
Discussion
Kidney fibrosis is a common feature that complicates many CKDs. However, our mechanistic understanding of how renal myofibroblasts arise and function is far from complete, hindering diagnosis, disease prediction and intervention. Our study helps to redress this knowledge gap by making two main discoveries, which demonstrate: the transcription factor, SOX9, is required for renal fibrosis; and, downstream of SOX9, the cytoskeletal factor, NAV3, is required by renal myofibroblasts for fibrogenesis. The findings in mouse mapped consistently to tissue from patients with chronic kidney disease.
Our observed distribution of SOX9 post-injury fits with its known role in tubule regeneration 2, 20 .
However, a series of findings collectively indicate a previously unappreciated, comprehensive role for the transcription factor in kidney fibrosis: its appearance in vitro as pericytes activate into myofibroblasts; its tissue colocalization with -SMA and PDGFRin myofibroblasts; and, upon deletion, reduced expression of a profibrotic gene set, and markedly diminished interstitial collagen and lessened scarring. These new insights are consistently analogous to findings in liver fibrosis (and regeneration) where SOX9 is central to HSC activation and fibrogenesis 7, 8, 12, 14, 15, [24] [25] [26] [27] [28] [29] [30] . The interorgan parallels are important for at least two reasons. Firstly, the prevalence of SOX9 in tissue biopsies and serum concentration of proteins encoded from its target genes could be prognostic for progressive renal fibrosis, as we have shown in liver 8, 12 ; and secondly, equivalence with the HSC imputes the renal pericyte as an important source of myofibroblasts in interstitial kidney fibrosis. How renal myofibroblasts arise has been contentious 31 . Our methodology here for renal pericyte-to-myofibroblast transition ought to have wide utility, including therapeutic screening, as an in vitro model of renal fibrogenesis.
Our genome-wide approach and differential expression analysis deciphered a broad repertoire of profibrotic SOX9 target genes. The range of genes encode ECM components including ten collagen subunits, consistent with the decreased interstitial scarring in SOX9 null kidneys post-UUO ( Supplementary Figure 4) . This strategy identified Nav3, a member of the neuron navigator gene family encoding actin-binding proteins with roles in actin remodeling 32 . NAV3 has not been previously associated with organ fibrosis or myofibroblasts.
NAV3 has been shown to promote development and migration of the liver and pancreatic buds in zebrafish 33 ; findings which are concordant with other known SOX9 functions 34 . We demonstrate that NAV3 is required for myofibroblast migration concordant with its stabilization of microtubules, which help guide neuronal projection 35 . Surprisingly, in breast and hepatocellular carcinoma cells it was the opposite, where NAV3 loss-of-function increased speed of migration 23, 36 . While superficially at odds with our findings and perhaps indicating a difference between primary and transformed cells, the more detailed study in breast cancer cells revealed the faster migration was in fact less persistent and more random 23 . Conversely, the authors showed over-expression of NAV3 enhanced directional persistence in response to growth factors, albeit more slowly. Collectively, this would fit with our overarching concept of activating pericytes inducing SOX9 to produce, in turn, NAV3 that enables chemotactic stimuli and gradients of growth factors, such as TGF-, to be followed to sites of renal injury. We also found that higher NAV3 levels proportionally favored more active (dephosphorylated) YAP. SOX9 itself is a YAP target gene 7, 8, 37 offering an explanation for how myofibroblasts might sustain an activated phenotype in renal fibrosis via SOX9-NAV3-YAP1-SOX9 circuitry. Finally, there are no drug treatments for renal fibrosis. SOX9, as a non-liganded transcription factor, would be hard to target. In contrast, NAV3 is an ATPase. Modulating enzymatic activity is a far more tractable approach for drug development.
In summary, we have discovered a fundamental role for SOX9 and its downstream target, NAV3, in driving myofibroblast migration and function in chronic kidney disease. The data help redress the shortfall in mechanistic understanding and open the door to new therapeutic options in renal fibrosis.
Methods
Mouse experiments
The Sox9 fl/fl ;RosaCreER mice have been described previously 8 
Human tissue
Following ethical approval and informed consent, human kidney biopsy samples were acquired from the Salford Kidney Study (Regional Ethics Committee Approval 15/NW/0818; IRAS 191926; n=3 for each disease-type). Tissue collection and handling was undertaken as previously described 8, 38, 39 .
Histology, immunohistochemistry, immunocytochemistry and in situ hybridization
Picro-sirius red (PSR) was used to stain kidney sections for collagen. The extent of scarring was determined by morphometric analysis of PSR. The 3D Histech Panoramic 250 Flash II slide scanner was used to acquire images of whole kidney. At 10 x magnification 10 images were selected from each slide at random and analyzed with Adobe Photoshop. Stained pixels were selected using the Colour Range tool and expressed as a fraction of the total number of pixels.
Immunohistochemistry was undertaken as previously 7, 8 . In brief, tissue was fixed in 4% paraformaldehyde and embedded in paraffin wax for sectioning at 5µm intervals. Heat induced epitope retrieval was performed in sodium citrate buffer, pH 6. Detection was performed using the following All quantification was carried out blind to the investigators following randomization of slides and acquired images.
Pericyte preparation
A modified version of the protocol in Schrimpf et al (2012) was used 40 . Briefly, the renal capsule was removed from both kidneys before mincing with a razor blade and digestion at 37°C for 30 min in HBSS+ (ThermoFisher) containing 0.8U/ml Liberase TM (Roche) and 1mg/ml DNAse (Sigma). 
qRT-PCR
Tissue was stored in RLT buffer at -80°C until use. RNA was extracted using an RNeasy kit (Qiagen), followed by DNAse I treatment (Sigma) and conversion into cDNA using a High Capacity RNA-to-cDNA kit (Life Technologies). Assays were performed using primers (Supplementary table 2 ) and a SYBR green master mix (Primerdesign) on a StepOnePlus system (Applied Biosciences). Ct values were standardized to two 'housekeeping' genes, GusB and ActinB, and relative quantification calculated using ΔΔCt methodology.
RNA sequencing
RNA was prepared 7 and RNAseq undertaken as previously described 41 . RNA quality checks, creation of a cDNA library and DNA fragmentation was performed by the University of Manchester Genomics Core Facility. RNAseq was undertaken in biological replicate using the Illumina HiSeq 4000 to generate 280-300 million reads across ipsilateral UUO and contralateral unaffected kidneys from Sox9 null and Sox9 control mice (8 samples total). Post-sequencing QC analysis was undertaken as previously 41 .
In brief, paired-end sequences were tested by FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), sequence adapters removed and reads quality trimmed using Trimmomatic_0.36 42 . Reads were mapped against the reference mouse genome (mm10/GRCm38) and counts per gene were calculated according to annotation from GENCODE M21 (http://www.gencodegenes.org/) using STAR_2.5.3 43 . Normalization, principal components analysis, and differential expression was undertaken with DESeq2_1.24.0 44 . Cluster analysis was performed using a κ-means clustering algorithm to place gene expression into groups. Pathways and networks associated with the differential gene expression were analyzed using Ingenuity Pathway Analysis (Ingenuity® Systems, www.ingenuity.com).
Western blot
Quantification of protein by Western blotting was carried out using standard techniques and the following primary and secondary antibodies: anti-α-SMA (SMA-R-7-CE, Leica Biosystems, dilution: 
Luciferase assay
Conserved SOX9 binding motifs surrounding the human NAV3 locus were identified using Mulan alignment (https://mulan.dcode.org/) and multiTF (https://multitf.dcode.org/) 48 . Approximately 100bp of the surrounding sequence was amplified by PCR from LX2 cells and cloned into the XhoI site of the pGL3+promoter vector (Promega) with corresponding empty vector as control. Mutated amplicons lacking the conserved ACAAT SOX9-binding motifs were also cloned into the same vector (coordinates and sequences in Supplementary Figure 6 and Supplementary Table 3 
Statistics
All statistical analyses were performed using GraphPad Prism 7 (GraphPad). Two-tailed T-tests were used for single comparisons. For multiple comparisons, 1-way or 2-way ANOVA was performed with Dunnett's post-hoc multiple comparisons test to identify the significance of individual comparisons. 
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